期刊文献+

自身免疫病血液系统损害的临床诊治和挑战 被引量:10

原文传递
导出
摘要 血液系统损害是自身免疫病主要的系统损害之一,在引起血液系统损害的自身免疫病中,最多见的是系统性红斑狼疮(SLE),其次为类风湿关节炎(RA),混合性结缔组织病(MCTD),原发性干燥综合征(pSS)等。约50%~86%的SLE患者在病情进行过程中会出现不同的血液系统损害,其中贫血约占60%~70%,白细胞减少约占33%~63%,血小板减少约占26%~58%t。
作者 齐文成
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2012年第10期649-650,共2页 Chinese Journal of Rheumatology
  • 相关文献

参考文献14

  • 1Fietta P, Delsante G, Quaini F. Hematologic manifestations ofconnective autoimmune disease. Clin Exp Rheumatol, 2009,27:140-154.
  • 2Beyan E,Beyan C,Turan M. Hematological presentation in sys-temic lupus erythematosus and its relationship with disease ac-tivity. Hematology, 2007, 12: 257-261.
  • 3张学增,张育,孙凌云,邹耀红,潘文友,王向党,潘解萍,张缪佳,谭魁麟,李晶,陈志伟,丁翔,钱先,达展云,陶娟,王美美.系统性红斑狼疮血液系统损害与疾病预后分析[J].中华风湿病学杂志,2011,15(2):101-104. 被引量:16
  • 4Font J, Cervera J, Ramos-Casals M, et al. Clasters of clinicaland features in systemic lupus erythmatosus: analysis of 600patients from a single center. Semin Arthritis Rheum, 2004, 33:217-230.
  • 5Kuwana M, Kaburaki J,Okayaki Y, et al. Two types of autoan-tibody-mediated thrombocytopenia in patients with systemic lupuserythmatosus. Rheumatology, 2006, 45: 851-854.
  • 6Ziakas PD, Rortsias JG, Giannouli S, et al. Suspects in the taleof lupus-associated thrombocytopenia. Clin Exp Immunol, 2006,145: 71-80.
  • 7赵海丰,李尚珠,杨仁池.系统性红斑狼疮相关血液系统疾病研究进展.国际输血及血液学杂志,2008,5: 443-446.
  • 8Ramos-Casals M,Font J,Garcia-Carrasco M, et al. PrimarySjogren syndrome hematologic patterns of disease expressioon.Medicine, 2002, 81: 281-292.
  • 9陈嘉林,黄晓明,曾学军,王玉,周明晓,马亚辉,李蓉生,沈悌.系统性红斑狼疮患者血液学异常的特点及其临床意义[J].中华医学杂志,2007,87(19):1330-1333. 被引量:19
  • 10Voulgarelis M, Giannouli S,Tasidou A, et al. Bone marrowhistological findings in systemic lupus erythematosus with hema-tologic abnomalites: a clinicopathological study. Ame J Hemat,2006’ 81: 590-597.

二级参考文献35

  • 1陈嘉林,李淑兰,徐闽,王海滨,葛昌文,李蓉生.血清转铁蛋白受体对贫血患者鉴别诊断的临床意义[J].中华内科杂志,2004,43(6):423-425. 被引量:12
  • 2邹农,华宝来,王书杰,朱铁楠,赵永强.利妥昔单抗治疗难治性特发性血小板减少性紫癜一例[J].中华医学杂志,2005,85(6):432-432. 被引量:4
  • 3中华医学会血液学学会血栓与止血学组.几种出血性疾病诊断(及疗效)标准的修订[J].中华血液学杂志,1995,16:331-331.
  • 4Portielje JE,Westendorp RG,Kluin-Nelemans HC.Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.Blood,2001,97:2549-2554.
  • 5Yang R,Han ZC.Pathogenesis and management of chronic idiopathic thrombocytopenie pttrpura:an update.Int J Hematol.2000,71:18-24.
  • 6Godeou B,PorcherR,Fain O,et al.Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:results of a prospective muhicenter phase 2 study.Blood,2008,112:999-1004.
  • 7Zhou z,Yang R.Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.Crit Rev Oncol Hematol,2008,65:21-31.
  • 8Rodeghiero F,Stasi R,Gemsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an intcmational working group.Blood,2009,113:2386-2393.
  • 9Zaja F,Battista ML,Pirrona MT,et al.Lower dose rituximab is active in adults patients with idiopathic thrnmbocytopenic purpura.Haematologica,2008,93:930-933.
  • 10Arnold DM,Dentali F,Crowther MA,et al.Systematic review:efficacy and safely of rituximab foradults with idiopathic thrombocytopenic purpura.Ann Intern Med,2007,146:25-33.

共引文献71

同被引文献94

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部